Prevention of Cardiovascular Disease and Mortality in Patients With Psoriasis or Psoriatic Arthritis: Translating Guidelines of Care to Better Outcomes for Patients With Psoriatic Disease
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 入组人数
- 520
- 试验地点
- 28
- 主要终点
- Change in LDL
研究概览
简要总结
The goal of this research is to test a novel centralized care coordinator program to assist patients with psoriatic disease in lowering their risk of cardiovascular disease through the application of standard of care approaches to improving modifiable cardiovascular risk factors.
详细描述
Psoriasis patients have an increased risk of cardiovascular disease and mortality but are less likely to have traditional cardiovascular risk factors identified or adequately managed. Care coordinators have previously been demonstrated to improve outcomes in patients with chronic diseases (such as comorbid diabetes and depression) and are now routinely embedded in primary care practices in integrated health systems. The goal of this research is to test a novel centralized care coordinator program to assist patients with psoriatic disease in lowering their risk of cardiovascular disease through the application of standard of care approaches to improving modifiable cardiovascular risk factors.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Other
- 盲法
- None
入排标准
- 年龄范围
- 40 Years 至 75 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Willing and able to provide informed consent
- •Male or female aged 40-75
- •Being seen by a dermatology provider in routine care for the primary encounter diagnosis of psoriasis
排除标准
- •Currently taking a prescription lipid lowering medication
- •Pregnant or planning pregnancy in the next 6 months
- •Has a known history of cardiovascular disease (MI, Stroke, coronary artery, cerebrovascular, or peripheral vascular disease)
研究组 & 干预措施
Care Coordination
干预措施: Care Coordinator Model (Other)
结局指标
主要结局
Change in LDL
时间窗: 6 months
Change in LDL cholesterol
次要结局
- Smoking status change(6 months)
- Change in 10-year cardiovascular (CV) risk(6 months)
- Addition of new medication(6 months)
- 50% LDL reduction(6 months)
- Change in blood pressure(6 months)
- Change in cholesterol(6 months)
- Change in non-HDL(6 months)
- Change in Physicians Global Assessment (PGA) psoriasis severity(6 months)
- 30% LDL reduction(6 months)
- LDL reduction under 100(6 months)
- Change in HDL(6 months)
- Change in HbA1c(6 months)
- Change in Weight(6 months)
- Change in general health(6 months)
- Change in reported psoriasis medication use(6 months)
- Change in dermatology life quality index (DLQI)(6 months)
- Change in physical activity level(6 months)
- Patient experience with Care Coordinator Model(6 months)
- Percent undergoing additional CV testing(6 months)
- Change in Body Surface Area (BSA) psoriasis severity(6 months)
- Change in physical activity days active(6 months)